J. Zacho

发表

Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes

A. Flint, K. C. Petri, S. Ingwersen, 2018, Diabetes, obesity & metabolism.

Does Greater Adiposity Increase Blood Pressure and Hypertension Risk?: Mendelian Randomization Using the FTO/MC4R Genotype

N. Timpson, B. Nordestgaard, G. Smith, 2009, Hypertension.

The Effect of Elevated Body Mass Index on Ischemic Heart Disease Risk: Causal Estimates from a Mendelian Randomisation Approach

N. Timpson, B. Nordestgaard, G. Davey Smith, 2012, PLoS medicine.

C-reactive protein levels and body mass index: Elucidating direction of causation through reciprocal Mendelian randomization

T. Frayling, N. Timpson, B. Nordestgaard, 2010, International Journal of Obesity.

Prothrombin and risk of venous thromboembolism, ischemic heart disease and ischemic cerebrovascular disease in the general population.

B. Nordestgaard, T. Schroeder, G. Jensen, 2010, Atherosclerosis.

Twice‐daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin‐naïve adults with Type 2 diabetes

E. Franek, J. Christiansen, J. Zacho, 2015, Diabetic medicine : a journal of the British Diabetic Association.

GREATER COMBINED REDUCTIONS IN HBA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VS COMPARATORS IN TYPE 2 DIABETES.

H. Rodbard, I. Hramiak, V. Aroda, 2019, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double‐blind randomized controlled trial (BEGIN: ADD TO GLP‐1 Study)

Lawrence A Leiter, P. Raskin, T. Bailey, 2016, Diabetes, obesity & metabolism.

A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin

T. Pieber, K. Lalić, J. Zacho, 2018, Diabetes Care.

[Changes in the smoking habits of Danes in the period 1970-1987].

J. Zacho, P. E. Nielsen, J. A. Olsen, 1988, Ugeskrift for laeger.

C-reactive protein and all-cause mortality--the Copenhagen City Heart Study.

B. Nordestgaard, A. Tybjaerg-hansen, J. Zacho, 2010, European heart journal.

C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach

B. Nordestgaard, J. Vestbo, P. Lange, 2010, Thorax.

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine in insulin-naïve subjects with type 2 diabetes (SUSTAIN 4)

J. DeVries, V. Aroda, J. Zacho, 2016 .

Reproductive outcome of patients undergoing in vitro fertilisation treatment and diagnosed with bacterial vaginosis or abnormal vaginal microbiota: a systematic PRISMA review and meta‐analysis

P. Humaidan, T. Haahr, J. Zacho, 2019, BJOG : an international journal of obstetrics and gynaecology.

Genetically elevated C-reactive protein and ischemic vascular disease.

Børge G Nordestgaard, Henrik Sillesen, B. Nordestgaard, 2008, The New England journal of medicine.

Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls

A. Folsom, M. den Heijer, M. Cushman, 2013, European Journal of Epidemiology.

Using genetic loci to understand the relationship between adiposity and psychological distress: a Mendelian Randomization study in the Copenhagen General Population Study of 53 221 adults

D. Lawlor, N. Timpson, B. Nordestgaard, 2011, Journal of internal medicine.

Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials

M. Nalls, A. Singleton, L. Ferrucci, 2011, The Lancet.

Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population.

B. Nordestgaard, M. Benn, G. Jensen, 2010, Journal of the American College of Cardiology.

C-Reactive Protein and Risk of Venous Thromboembolism in the General Population

B. Nordestgaard, J. Zacho, A. Tybjærg‐Hansen, 2010, Arteriosclerosis, thrombosis, and vascular biology.

C-reactive protein and the risk of cancer: a mendelian randomization study.

S. Bojesen, B. Nordestgaard, K. Allin, 2010, Journal of the National Cancer Institute.

Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example

M. Davies, J. Buse, V. Aroda, 2019, Diabetes, obesity & metabolism.

The methylenetetrahydrofolate reductase C677T genotype and the risk of obesity in three large population-based cohorts

Shah Ebrahim, Debbie A Lawlor, Sarah J Lewis, 2008, European journal of endocrinology.

The MTHFR C677T genotype and the risk of obesity in 3 large population based cohorts Running title: MTHFR C677T and obesity

D. Lawlor, S. Lewis, B. Nordestgaard, 2008 .

Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C>T polymorphism and risk of cancer: Cross‐sectional and prospective studies and meta‐analyses of 75,000 cases and 93,000 controls

S. Bojesen, B. Nordestgaard, J. Zacho, 2011, International journal of cancer.

Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial

Yuichiro Yamada, H. Watada, A. Kiyosue, 2018, Diabetes, obesity & metabolism.

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes

Y. Terauchi, D. Yabe, Y. Seino, 2017, Diabetes, obesity & metabolism.

Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation

Jack Bowden, Alex P. Reiner, Meena Kumari, 2008 .

Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme

V. Woo, J. Zacho, C. Desouza, 2018, Diabetes, obesity & metabolism.

Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis

A. Flint, S. Ingwersen, J. Zacho, 2018, Diabetes Therapy.

Increased Baseline C-Reactive Protein Concentrations Are Associated with Increased Risk of Infections: Results from 2 Large Danish Population Cohorts.

B. Nordestgaard, J. Zacho, T. Benfield, 2016, Clinical chemistry.

Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co‐formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial

H. Rodbard, T. Pieber, J. Zacho, 2016, Diabetes, obesity & metabolism.

C‐reactive protein, genetically elevated levels and risk of ischemic heart and cerebrovascular disease

B. Nordestgaard, J. Zacho, A. Tybjærg‐Hansen, 2009, Scandinavian Journal of Clinical and Laboratory Investigation.

A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects

A. Flint, J. Zacho, S. Irie, 2018, Advances in Therapy.

Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?

B. Nordestgaard, J. Zacho, 2009, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial

Y. Iwamoto, J. Zacho, J. Ekelund, 2016, Journal of diabetes investigation.

Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials

Jonathan E. Dickerson, R. Collins, M. Nalls, 2011, The Lancet.

Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials

M. Nalls, A. Singleton, L. Ferrucci, 2011, The Lancet.

Does Greater Adiposity Increase Blood Pressure and Hypertension Risk?: Mendelian Randomization Using the FTO/MC4R Genotype

N. Timpson, B. Nordestgaard, G. Smith, 2009, Hypertension.

Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials

R. Sofat, J. Zacho, John Hardy, 2011 .

A. Folsom, M. den Heijer, M. Cushman, 2013, European Journal of Epidemiology.

C-reactive protein and the risk of cancer: a mendelian randomization study.

S. Bojesen, B. Nordestgaard, K. Allin, 2010, Journal of the National Cancer Institute.

Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials

M. Nalls, A. Singleton, L. Ferrucci, 2011, The Lancet.

A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin

T. Pieber, K. Lalić, J. Zacho, 2018, Diabetes Care.